文献速递糖尿病

进展可能性评分识别儿童公共卫生筛查中症状前1型糖尿病的亚阶段

Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening.
PubMed 文献 · Diabetologia · 2022-08-27

研究基于德国巴伐利亚Fr1da公共卫生筛查项目154,462名1.75-10岁儿童,对447名多种胰岛自身抗体阳性儿童进行分期,开发进展可能性评分以识别2年内进展至3期(临床)1型糖尿病的1期儿童。结果显示,2期儿童2年进展风险为48%(95%CI 34,58),评分高于90百分位的1b期儿童2年进展风险为46%(95%CI 21,63),而1a期仅为4.1%(95%CI 1.4,6.7)。

要点

  • 筛查儿童中0.027%存在未诊断的临床1型糖尿病,0.038%存在未诊断的症状前2期或1b期1型糖尿病。
  • 2期1型糖尿病儿童2年进展至3期的风险为48%(95%CI 34,58),年化风险28%。
  • 进展可能性评分高于90百分位的1b期儿童2年进展风险为46%(95%CI 21,63),低于90百分位的1a期为4.1%(95%CI 1.4,6.7)。

核心结论

  • 公共卫生筛查发现0.027%的儿童存在未诊断的临床1型糖尿病,0.038%存在未诊断的症状前2期或1b期1型糖尿病,其中约50%在2年内进展为临床1型糖尿病。

研究设计与样本

  • 研究基于德国巴伐利亚Fr1da公共卫生筛查项目,纳入1.75-10岁儿童共154,462名,检测胰岛自身抗体。
  • 对多种胰岛自身抗体阳性儿童进行OGTT和HbA1c评估,以诊断症状前1期(血糖正常)或2期(血糖异常)1型糖尿病。
  • 采用Cox比例风险模型和惩罚逻辑回归分析自身抗体、遗传、代谢和人口学信息,开发进展可能性评分以识别2年内进展至3期的1期儿童。

主要发现

  • 447名多种胰岛自身抗体阳性儿童中,364名(81.4%)完成分期。
  • 筛查儿童中检出未诊断的3期1型糖尿病41例(0.027%)、症状前2期30例(0.019%)和1期293例(0.19%)。
  • 2期1型糖尿病儿童2年进展至3期的风险为48%(95%CI 34,58),年化风险28%。
  • 1期儿童中,HbA1c、胰岛抗原2自身抗体阳性及滴度、以及OGTT 90分钟值可预测进展。
  • 进展可能性评分将1期儿童分为≤90百分位(1a期,n=258)和>90百分位(1b期,n=29;0.019%),2年进展至3期风险分别为4.1%(95%CI 1.4,6.7)和46%(95%CI 21,63)。

关键数值与推荐

  • 症状前1期定义为血糖正常,2期定义为血糖异常。
  • 进展可能性评分≤90百分位为1a期,>90百分位为1b期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of this study was to develop strategies that identify children from the general population who have late-stage presymptomatic type 1 diabetes and may, therefore, benefit from immune intervention. METHODS: We tested children from Bavaria, Germany, aged 1.75-10 years, enrolled in the Fr1da public health screening programme for islet autoantibodies (n=154,462). OGTT and HbA1c were assessed in children with multiple islet autoantibodies for diagnosis of presymptomatic stage 1 (normoglycaemia) or stage 2 (dysglycaemia) type 1 diabetes. Cox proportional hazards and penalised logistic regression of autoantibody, genetic, metabolic and demographic information were used to develop a progression likelihood score to identify children with stage 1 type 1 diabetes who progressed to stage 3 (clinical) type 1 diabetes within 2 years. RESULTS: Of 447 children with multiple islet autoantibodies, 364 (81.4%) were staged. Undiagnosed stage 3 type 1 diabetes, presymptomatic stage 2, and stage 1 type 1 diabetes were detected in 41 (0.027% of screened children), 30 (0.019%) and 293 (0.19%) children, respectively. The 2 year risk for progression to stage 3 type 1 diabetes was 48% (95% CI 34, 58) in children with stage 2 type 1 diabetes (annualised risk, 28%). HbA1c, islet antigen-2 autoantibody positivity and titre, and the 90 min OGTT value were predictors of progression in children with stage 1 type 1 diabetes. The derived progression likelihood score identified substages corresponding to ≤90th centile (stage 1a, n=258) and >90th centile (stage 1b, n=29; 0.019%) of stage 1 children with a 4.1% (95% CI 1.4, 6.7) and 46% (95% CI 21, 63) 2 year risk of progressing to stage 3 type 1 diabetes, respectively. CONCLUSIONS/INTERPRETATION: Public health screening for islet autoantibodies found 0.027% of children to have undiagnosed clinical type 1 diabetes and 0.038% to have undiagnosed presymptomatic stage 2 or stage 1b type 1 diabetes, with 50% risk to develop clinical type 1 diabetes within 2 years.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Weiss A, Zapardiel-Gonzalo J, Voss F, et al. Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening. Diabetologia. 2022. PMID: 36028774. doi:10.1007/s00125-022-05780-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。